Combo Disappoints in Metastatic Prostate Cancer
Combining the tyrosine kinase inhibitor saracatinib with docetaxel does not benefit patients with metastatic, castration-resistant prostate cancer (mCRPC), according to
Read more
Combining the tyrosine kinase inhibitor saracatinib with docetaxel does not benefit patients with metastatic, castration-resistant prostate cancer (mCRPC), according to
Read moreIn Germany, the life depends on maintenance with the income: Overall, significantly fewer women and men with the lowest income,
Read moreFrance’s health minister on Sunday announced a new investigation into the births of several babies with upper limb defects in
Read moreDoing it for the ‘gram can have serious consequences. One Instagram model learned this the hard way while on vacation in
Read more